Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers

Journal of Clinical Oncology

Volumn 21, Issue 6, 2003, Pages 1167-1173

  Kantarjian, Hagop M ^a   Gandhi, Varsha ^a   Kozuch, Peter ^a   Faderl, Stefan ^a   Giles, Francis ^a   Cortes, Jorge ^a   O'Brien, Susan ^a   Ibrahim, Nuhad ^a   Khuri, Fadlo ^a   Du, Min ^a   Rios, Mary Beth ^a   Jeha, Sima ^a   McLaughlin, Peter ^a   Plunkett, William ^a   Keating, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT RESPONSE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; BLOOD DISEASE; BONE MARROW; BREAST TUMOR; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GASTROINTESTINAL TUMOR; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LUNG TUMOR; MALE; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; BONE MARROW; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL NEOPLASMS; HEMATOLOGIC NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LIVER; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 0037445122     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.031     Document Type: Article

References (25)

1. Estey EH: Therapeutic options for acute myelogenous leukemia. Cancer 92:1059-1073, 2001
2. Santoro A, Bredenfeld H, Devizzi L, et al: Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 18:2615-2619, 2000
3. Fossa A, Santoro A, Hiddemann W, et al: Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 17:3786-3792, 1999
4. Silverman LR, Demakos EP, Bercedis L, et al: A randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002
5. Wijermans P, Lubbert M, Verhoef G, et al: Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962, 2000
6. Santini V, Kantarjian H, Issa, J: Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann Intern Med 134:573-586, 2001
7. Gandhi V, Plunkett W, Rodriguez C, et al: Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16:3607-3615, 1998
8. Keating M, O'Brien S, Plunkett W, et al: Fludarabine phosphate: A new active agent in hematologic malignancies. Semin Hematol 31:28-39, 1994
9. Piro LD, Carrera CJ, Carson DA, et al: Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med 322:1117-1121, 1990
10. Avramis VI, Plunkett W: 2-Fluoro-ATP: A toxic metabolite of 9-b-D-arabinofuranosyl-2-fluoroadenine. Biochem Biophys Res Comm 113:35-43, 1983
11. Avramis VI, Plunkett W: Metabolism of 9-b-D-arabinofuranosyl-2- fluoroadenine 5′-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv 1:1-10, 1983
12. Huang P, Plunkett W: Phosphorolytic cleavage of 2-fluoroadenine from 9-b-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli: A pathway for 2-fluoro-ATP production. Biochem Pharm 36:2945-2952, 1987
13. Parker WB, Shaddix SC, Chang CH, et al: Effects of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51:2386-2394, 1991
14. Plunkett W, Gandhi V: Purine and pyrimidine nucleoside analogs, in Giaccone G, Schilsky R, Sondel P (eds): Cancer Chemotherapy and Biologic Response Modifiers, Annual 19. Elsevier Science, BV, Amsterdam, the Netherlands, 2001, pp 21-45
15. Plunkett W, Hug V, Keating M, et al: Quantitation of 1-β-D- arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D- arabinofuranosylcytosine therapy. Cancer Res 40:588-591, 1980
16. Gandhi V, Chen W, Ayres M, et al: Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol 50:85-94, 2002
17. Rodriguez CO Jr, Plunkett W, Paff MT, et al: A high-pressure liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B 745:421-430, 2000
18. Collins J, Grieshaber C, Chabner B: Trials based on preclinical drug development. J Natl Cancer Inst 82:1321-1326, 1990
19. Noker P, Duncan G, El Dareer S, et al: Disposition of 9-β-D-arabinofuranosyl-2-fluoradenine 5′-phosphate in mice and dogs. Cancer Treat Rep 67:445-456, 1983
20. Malspeis L, Grever M, Staubus A, et al: Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin Oncol 17:18-32, 1990
21. Warrell R, Berman E: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed CNS toxicity. J Clin Oncol 4:74-79, 1986
22. Krenitsky TA, Tuttle JV, Koszalka GW, et al: Deoxycytidine kinase from calf thymus: Substrate and inhibitor specificity. J Biol Chem 251:4055-4061, 1976
23. Wang L, Karlsson A, Arner ES, et al: Substrate specificity of mitochondrial 2′-deoxyguanosine kinase: Efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem 268:22847-22852, 1983
24. Shewach DS, Reynolds KK, Hertel L, et al: Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 42:518-524, 1992
25. Parker WB, Shaddix SC, Rose LM, et al: Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)adenine 2-chloro-9-(2-deoxy- 2,2-difluoro-β-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 55:515-520, 1999